What Are Embryonic Stem Cells (ESCs)? Regenerative Potential and Important Limitations

Embryonic stem cells (ESCs) are stem cells cultured in a laboratory. They are derived from the inner cell mass (ICM) of an early-stage embryo before implantation, during the blastocyst stage, which generally occurs 5–6 days after fertilization. These cells have not yet developed into specialized cells. Under suitable conditions, they can continue to multiply while retaining their stem-cell properties (self-renewal**) and can develop into almost any cell type in the body (pluripotency**), including skin, nerve, muscle, bone, and blood cells, as well as liver, pancreatic, and lung cells.

After fertilization, the egg begins to divide continuously. A single cell develops into a group of cells before becoming a blastocyst, generally around days 5–6 after fertilization. At this stage, the embryo resembles a fluid-filled structure and consists of two important cell groups:

• Trophectoderm: The outer layer of cells, which develops into extraembryonic tissues and plays a role in attachment to and implantation in the uterine wall.
• Inner Cell Mass (ICM): The group of cells inside the embryo that develops into the tissues and organs of the body.

Embryonic stem cells originate from the ICM. Researchers isolate this group of cells from a blastocyst and culture it in a laboratory under carefully controlled conditions. In general, the embryos used are created through in vitro fertilization (IVF) and are not intended for further reproductive use. Their use requires donor consent and must be conducted in accordance with strict regulatory and ethical requirements.

During culture, researchers control the conditions so that the cells continue to multiply while remaining stem cells rather than immediately developing into specialized cells. This process can establish an embryonic stem cell line for further medical research and development.

After ESCs have been cultured, guided to develop into the desired target cells, and subjected to rigorous quality-control procedures, a physician may administer them to the area requiring regeneration through an appropriate method, such as direct injection or transplantation into tissue. The cells may then act through processes including:

• Adapting to the body’s environment: Transplanted cells adapt to the environment of the target area. However, some cells may not survive and may be eliminated by the body.
• Attaching to or connecting with existing tissue: Some surviving cells may attach to, integrate with, or connect to cells and tissues in the target area. This depends on the cell type and the transplantation site.
• Maturing and performing specialized functions: Surviving cells may continue to adapt and mature inside the body before carrying out functions associated with their cell type. They may help replace lost cells, support existing cells, or contribute to the recovery of tissue function in the target area.

One research example developed human embryonic stem cells (hESCs), line ESI-017, into PC-M perivascular progenitor cells. These cells share certain characteristics and functions with pericytes, which surround blood vessels and help support and maintain vascular stability. When human umbilical vein endothelial cells (HUVECs) were co-cultured with PC-M cells at a ratio of 20:1, PC-M cells helped produce a denser vessel-like network that degraded less and remained stable for up to six days, whereas networks formed from HUVECs alone began to break down after day two.

This study indicates that PC-M cells may help support and improve the stability of vascular endothelial cell networks. However, these findings are still in vitro evidence, and further studies in animals and humans are required (Greenwood-Goodwin et al., 2016).

Physicians should schedule follow-up appointments after treatment to evaluate the body’s response and continuously monitor safety. Because cells developed from ESCs originate outside the recipient’s body, they may trigger an immune response or rejection. In some cases, a physician may consider immunosuppressive medication to reduce rejection and improve the cells’ chances of surviving and functioning in the body. However, outcomes after transplantation may differ between individuals depending on factors such as cell type and purity, the transplantation site and method, the severity of the condition, and each person’s individual response.

Stem-cell types differ in their source, ability to develop into different cell types, capacity for multiplication, and readiness for medical use. Embryonic stem cells differ from other sources as follows:

• Embryonic Stem Cells: Stem cells derived from a blastocyst, with pluripotent properties. They can multiply continuously and develop into almost any specialized cell type in the body. They have significant potential in medicine and regenerative medicine, but their development and quality must be controlled and evaluated very strictly.
• ES Organ-Specific Cells: Specialized stem cells developed from high-quality human embryonic stem cells (hESCs) and produced under cGMP standards using PureStem® technology and directed differentiation. This process guides cells to become embryonic progenitor cells for specific lineages, such as the brain, nervous system, liver, kidney, muscle, lung, pancreas, thyroid, or heart. Clonal isolation is then used to obtain a homogeneous cell population. Cell-surface markers and gene-expression analysis are used for characterization, resulting in a cell population with consistent properties and reported purity of approximately 95–100%.
• Allogeneic Human Mesenchymal Stromal Cells (MSCs): Cells obtained from young donors and isolated from bone marrow, adipose tissue, umbilical cord tissue, placenta, and certain other tissues. Their advantages include a younger cellular profile and similarity to cells in the human body, which may reduce the risk of cellular abnormalities. However, MSCs have a more limited differentiation capacity than embryonic stem cells, and cell quality depends on the source, donor age, and manufacturing process.
• Organ-Specific MSCs: An approach involving the development of MSC-based stem cells with greater specificity or targeting toward a particular organ, such as cartilage, the heart, liver, or the nervous system, to support treatment and regeneration. This type of stem cell remains a promising area for future medical applications.
• Autologous Stem Cells: Stem cells collected from the patient’s own blood, bone marrow, or adipose tissue. Because they come from the same individual, they are generally compatible with the body and have a lower risk of immune rejection. However, cell quality depends on age and health, and the cells must undergo collection and preparation before use.

The use of embryonic stem cells should be considered under the supervision of an experienced specialist and should involve cells from a high-quality, traceable source. The risks may increase when the cells do not meet appropriate standards or when their development is not fully controlled. Potential risks include the formation of teratomas from residual undifferentiated cells, immune rejection, and infection.

For this reason, the use of embryonic stem cells for treatment and regeneration must undergo rigorous evaluation, including laboratory testing, research and clinical trials, and approval from relevant regulatory authorities. It is important to understand that evidence regarding the safety and long-term outcomes of embryonic stem-cell use remains limited, and further research is necessary. This approach cannot replace standard medical treatment, and outcomes may vary according to multiple individual factors.

Embryonic stem cells, or ESCs, are stem cells derived from the inner cell mass of a blastocyst. Their key properties are the ability to multiply continuously and develop into almost any cell type in the body. As a result, they have attracted significant interest in research, medicine, and the development of cell-therapy approaches. However, because this field remains relatively new, further study is needed regarding effectiveness, safety, ethics, and the legal requirements that differ between countries.

LINNA Clinic currently does not offer stem-cell services using cells developed from embryonic stem cells. The clinic’s stem-cell services use mesenchymal stem cells (MSCs), which are not derived from embryos. Those interested may consult LINNA Clinic’s specialist medical team for a detailed health assessment, consideration of the suitability of each stem-cell approach, and an individualized care plan under medical supervision.

Contact us at Tel. 063-609-8888, WhatsApp +66 91 979 9554, or LINE: @linnaclinics